316 112

Full metadata record

DC FieldValueLanguage
dc.contributor.author이근화-
dc.date.accessioned2021-05-18T02:50:28Z-
dc.date.available2021-05-18T02:50:28Z-
dc.date.issued2020-03-
dc.identifier.citationPLOS NEGLECTED TROPICAL DISEASES, v. 14, no. 3, article no. e0007813en_US
dc.identifier.issn1935-2727-
dc.identifier.urihttps://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007813-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/162242-
dc.description.abstractSevere fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease caused by SFTS virus (SFTSV) infection. Despite a gradual increase of SFTS cases and high mortality in endemic regions, no specific viral therapy nor vaccine is available. Here, we developed a single recombinant plasmid DNA encoding SFTSV genes, Gn and Gc together with NP-NS fusion antigen, as a vaccine candidate. The viral antigens were fused with Fms-like tyrosine kinase-3 ligand (Flt3L) and IL-12 gene was incorporated into the plasmid to enhance cell-mediated immunity. Vaccination with the DNA provides complete protection of IFNAR KO mice upon lethal SFTSV challenge, whereas immunization with a plasmid without IL-12 gene resulted in partial protection. Since we failed to detect antibodies against surface glycoproteins, Gn and Gc, in the immunized mice, antigen-specific cellular immunity, as confirmed by enhanced antigen-specific T cell responses, might play major role in protection. Finally, we evaluated the degree of protective immunity provided by protein immunization of the individual glycoprotein, Gn or Gc. Although both protein antigens induced a significant level of neutralizing activity against SFTSV, Gn vaccination resulted in relatively higher neutralizing activity and better protection than Gc vaccination. However, both antigens failed to provide complete protection. Given that DNA vaccines have failed to induce sufficient immunogenicity in human trials when compared to protein vaccines, optimal combinations of DNA and protein elements, proper selection of target antigens, and incorporation of efficient adjuvant, need to be further investigated for SFTSV vaccine development.en_US
dc.description.sponsorshipThis research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (HI15C2891) and by the National Research Foundation of Korea (grant no. 2017M3A9E4061998), which are funded by the government of South Korea. JGK, KJ, HC, YK, HIK, and HJR received a scholarship from the BK21-plus education program provided by the National Research Foundation of Korea. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.en_US
dc.language.isoenen_US
dc.publisherPUBLIC LIBRARY SCIENCEen_US
dc.subjectGENEen_US
dc.subjectPATHOGENESISen_US
dc.subjectINFECTIONen_US
dc.subjectRESPONSESen_US
dc.titleVaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice.en_US
dc.typeArticleen_US
dc.identifier.doi10.1371/journal.pntd.0007813-
dc.relation.page1-16-
dc.relation.journalPLOS NEGLECTED TROPICAL DISEASES-
dc.contributor.googleauthorKang, Jun-Gu-
dc.contributor.googleauthorJeon, Kyeongseok-
dc.contributor.googleauthorChoi, Hooncheol-
dc.contributor.googleauthorKim, Yuri-
dc.contributor.googleauthorKim, Hong-Il-
dc.contributor.googleauthorRo, Hyo-Jin-
dc.contributor.googleauthorSeo, Yong Bok-
dc.contributor.googleauthorShin, Jua-
dc.contributor.googleauthorChung, Junho-
dc.contributor.googleauthorLee, Keun Hwa-
dc.relation.code2020047697-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidyomust7-
dc.identifier.orcidhttp://orcid.org/0000-0001-9600-461X-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE